Literature DB >> 12540528

Tacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria.

Nicolas Simon1, Christophe Morin, Saïk Urien, Jean-Paul Tillement, Bernard Bruguerolle.   

Abstract

1. Tacrolimus and sirolimus are potent immunosuppressors used in transplantation. Tacrolimus has been suspected to alter mitochondrial respiration of different tissues but sirolimus has not been evaluated. 2. We evaluated the in vitro effect of tacrolimus and sirolimus on oxidative phosphorylation of isolated rat kidney mitochondria. 3. Oxygen consumption was measured with a Clark-type electrode. Tacrolimus and sirolimus increased the resting rate (state 4) and had no significant effect on ADP-stimulated respiration (state 3). The decrease of respiratory control ratio was concentration-dependent with a biphasic curve for tacrolimus. The EC(50)s were 3.4 x 10(-11) M and 2.3 x 10(-8) M for tacrolimus and 4.4 x 10(-10) M for sirolimus. The maximal inhibition was 20 and 14% for tacrolimus and sirolimus, respectively. 4. Tacrolimus and sirolimus had an uncoupling effect on oxidative phosphorylation related to a decrease of the inner membrane fluidity. At the opposite of cyclosporin A, no effect on swelling or Ca(2+) fluxes was observed. 5. All events occurred at therapeutic concentrations and then could appear during long-term treatment. Cellular consequences such as chronic nephrotoxicity with tacrolimus are suggested. The risk of cyclosporin A nephrotoxicity potentiation by sirolimus is discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12540528      PMCID: PMC1573667          DOI: 10.1038/sj.bjp.0705038

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function.

Authors:  V Pelekanou; A E Trezise; A L Moore; J E Kay
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

2.  In vitro effects of cyclosporine and FK 506 on the renal cortex.

Authors:  S J Prasad; J McCauley; G Salama; T E Starzl; S A Murray
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model.

Authors:  T F Andoh; J Lindsley; N Franceschini; W M Bennett
Journal:  Transplantation       Date:  1996-08-15       Impact factor: 4.939

4.  MicroPharm-K, a microcomputer interactive program for the analysis and simulation of pharmacokinetic processes.

Authors:  S Urien
Journal:  Pharm Res       Date:  1995-08       Impact factor: 4.200

5.  Modulation of energy status and cytotoxicity induced by FK506 and cyclosporin A in a renal epithelial cell line.

Authors:  F Massicot; C Martin; H Dutertre-Catella; S Ellouk-Achard; C Pham-Huy; M Thevenin; P Rucay; J M Warnet; J R Claude
Journal:  Arch Toxicol       Date:  1997       Impact factor: 5.153

6.  FK506 increases permeability in rat intestine by inhibiting mitochondrial function.

Authors:  K L Madsen; N L Yanchar; D L Sigalet; T Reigel; R N Fedorak
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

7.  Comparison of the effects of the immunosuppressive agents FK 506 and cyclosporin A on rat kidney mitochondria.

Authors:  W Henke; K Jung
Journal:  Biochem Pharmacol       Date:  1993-09-01       Impact factor: 5.858

8.  Inhibition of the mitochondrial permeability transition by cyclosporin A during long time frame experiments: relationship between pore opening and the activity of mitochondrial phospholipases.

Authors:  K M Broekemeier; D R Pfeiffer
Journal:  Biochemistry       Date:  1995-12-19       Impact factor: 3.162

9.  Temperature-induced changes in fluorescence properties as a probe of porphyrin microenvironment in lipid membranes. 2. The partition of hematoporphyrin and protoporphyrin in mitochondria.

Authors:  F Ricchelli; S Gobbo; G Jori; C Salet; G Moreno
Journal:  Eur J Biochem       Date:  1995-10-01

Review 10.  Biochemical and molecular investigations in respiratory chain deficiencies.

Authors:  P Rustin; D Chretien; T Bourgeron; B Gérard; A Rötig; J M Saudubray; A Munnich
Journal:  Clin Chim Acta       Date:  1994-07       Impact factor: 3.786

View more
  13 in total

1.  A Combined N-terminomics and Shotgun Proteomics Approach to Investigate the Responses of Human Cells to Rapamycin and Zinc at the Mitochondrial Level.

Authors:  Joanna Bons; Charlotte Macron; Catherine Aude-Garcia; Sebastian Alvaro Vaca-Jacome; Magali Rompais; Sarah Cianférani; Christine Carapito; Thierry Rabilloud
Journal:  Mol Cell Proteomics       Date:  2019-03-15       Impact factor: 5.911

2.  Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction.

Authors:  Nassir Rostambeigi; Ian R Lanza; Petras P Dzeja; Michael C Deeds; Brian A Irving; Honey V Reddi; Pranathi Madde; Song Zhang; Yan W Asmann; Jarett M Anderson; Jill M Schimke; K Sreekumaran Nair; Norman L Eberhardt; Yogish C Kudva
Journal:  Transplantation       Date:  2011-03-27       Impact factor: 4.939

3.  Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.

Authors:  Hemant Sarin
Journal:  Mol Clin Oncol       Date:  2015-12-16

4.  Study of mitochondrial swelling, membrane fluidity and ROS production induced by nano-TiO2 and prevented by Fe incorporation.

Authors:  Tejal Barkhade; Santosh Kumar Mahapatra; Indrani Banerjee
Journal:  Toxicol Res (Camb)       Date:  2019-07-24       Impact factor: 3.524

5.  A case of severe osteomalacia secondary to phosphate diabetes in a renal transplant recipient.

Authors:  Johnny Sayegh; Jean-François Augusto; Daniel Chappard; Paolo Insalaco; Jean-François Subra
Journal:  Int Urol Nephrol       Date:  2012-09-19       Impact factor: 2.370

Review 6.  Benefit-risk assessment of sirolimus in renal transplantation.

Authors:  Dirk R J Kuypers
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

7.  Frailty after lung transplantation is associated with impaired health-related quality of life and mortality.

Authors:  Aida Venado; Nicholas A Kolaitis; Chiung-Yu Huang; Ying Gao; David V Glidden; Allison Soong; Nicole Sutter; Patricia P Katz; John R Greenland; Daniel R Calabrese; Steven R Hays; Jeffrey A Golden; Rupal J Shah; Lorriana E Leard; Jasleen Kukreja; Tobias Deuse; Paul J Wolters; Kenneth Covinsky; Paul D Blanc; Jonathan P Singer
Journal:  Thorax       Date:  2020-05-06       Impact factor: 9.139

8.  Hypomagnesemia and increased risk of new-onset diabetes mellitus after transplantation in pediatric renal transplant recipients.

Authors:  Wesley Hayes; Sheila Boyle; Adrian Carroll; Detlef Bockenhauer; Stephen D Marks
Journal:  Pediatr Nephrol       Date:  2016-12-30       Impact factor: 3.714

9.  Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro.

Authors:  Elena Matsa; Paul W Burridge; Kun-Hsing Yu; John H Ahrens; Vittavat Termglinchan; Haodi Wu; Chun Liu; Praveen Shukla; Nazish Sayed; Jared M Churko; Ningyi Shao; Nicole A Woo; Alexander S Chao; Joseph D Gold; Ioannis Karakikes; Michael P Snyder; Joseph C Wu
Journal:  Cell Stem Cell       Date:  2016-08-18       Impact factor: 24.633

10.  An Integrated Transcriptomic Approach to Identify Molecular Markers of Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients.

Authors:  Erika T Rhone; Elissa Bardhi; Sai Vineela Bontha; Patrick D Walker; Jorge A Almenara; Catherine I Dumur; Helen Cathro; Daniel Maluf; Valeria Mas
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.